### **SARS-Verbund**




**SARS, 2003** 




MERS, 2013

#### Coronavirus-Erkrankungen in der Veterinärmedizin

Name	Klinisches Bild	Virusbeschreibung
PEDV	Diarrhoe	1977
TGEV	Diarrhoe	1946
PRCV	Diarrhoe, Respirationstrakt-Infektion	1990
CCoV	Diarrhoe	1971
FIPV	Schwere systemische Infektion	1968
Bovine CoV	Diarrhoe, Respirationstrakt-Infektion	1972
MHV	Schwere systemische Infektion	1949
IBV	Respirationstrakt-Infektion	1941




# Weltweite Studien über Fledermaus-Coronaviren, 2013



## Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes

Jan Felix Drexler<sup>a,1</sup>, Andreas Geipel<sup>b,1</sup>, Alexander König<sup>b</sup>, Victor M. Corman<sup>a</sup>, Debby van Riel<sup>c</sup>, Lonneke M. Leijten<sup>c</sup>, Corinna M. Bremer<sup>b</sup>, Andrea Rasche<sup>a</sup>, Veronika M. Cottontail<sup>d,e</sup>, Gael D. Maganga<sup>f</sup>, Mathias Schlegel<sup>g</sup>, Marcel A. Müller<sup>a</sup>, Alexander Adam<sup>h</sup>, Stefan M. Klose<sup>d</sup>, Aroldo José Borges Carneiro<sup>i</sup>, Andreas Stöcker<sup>j</sup>, Carlos Roberto Franke<sup>i</sup>, Florian Gloza-Rausch<sup>a,k</sup>, Joachim Geyer<sup>l</sup>, Augustina Annan<sup>m</sup>, Yaw Adu-Sarkodie<sup>n</sup>, Samuel Oppong<sup>n</sup>, Tabea Binger<sup>a</sup>, Peter Vallo<sup>d,o</sup>, Marco Tschapka<sup>d,e</sup>, Rainer G. Ulrich<sup>g</sup>, Wolfram H. Gerlich<sup>b</sup>, Eric Leroy<sup>f,p</sup>, Thijs Kuiken<sup>c</sup>, Dieter Glebe<sup>b,1,2</sup>, and Christian Drosten<sup>a,1,2</sup>






Drexler/Geipel, PNAS 2013

#### HCoV-229E


## Prototypic human common cold CoV



### MERS-related CoV in *Neoromicia zuluensis* (Vespertilionidae)

**LETTERS** 

Close Relative of Human Middle East Respiratory Syndrome Coronavirus in Bat, South Africa recently described bat alphacoronaviruses from South Africa (4). The other positive specimen, termed PML/2011, was from an adult female *Neoromicia* cf. *zuluensis* bat sampled in 2011; the specimen yielded a novel betacoronavirus (GenBank accession no. KC869678). Online Technical Appen-



Ithete et al, EID, 2013

#### **MERS-Coronavirus in Fledermäusen**





#### **MERS: Kamele als Zwischenwirt**

THE LANCET Infectious Diseases

Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study

Chantal B E M. Reusken", Bart L. Haagmans", Marcel A Müller", Carlos Gutierrez, Gert-Jan Godeke, Benjamin Meyer, Doreen Muth, V. Stalin Raj. Laura Smits-De Vries, Victor M. Corman, Jan-Felix Drexler, Saskia L. Smits, Yasmin E El Tahir, Rita De Sousa, Janko van Beek, Norbert Nowotny, Kees van Maanen, Ezequiel Hidalgo-Hermoso, Berend-Jan Bosch, Peter Rottier, Albert Osterhaus, Christian Gortázar-Schmidt, Christian Drosten, Marion P G Koopmans




Figure 1: Reactivity of Ilvestock sera with three coronavirus 51 antigers. Fluorescent intensities per antigen at a serum dilution of 1/20. Black lines indicate median. Dashed line is cutoff of the assay, RFU-relative fluorescence units. SARS: CoV-severe acute respiratory syndrome coronavirus. HCoV-human coronavirus. MERS-CoV-Middle East respiratory syndrome coronavirus.

» recIFA und Neutralisationstest

» Neutralisierende Antikörper

Kanarische Inseln: 14% (N=105)


Oman: 100% (N=50)

– Emirate: >90% (N=651)

Ägypten: 90% (N=310)

Jordanien: 11/11

Kein Nachweis in anderen Nutztieren (Schafe, Ziegen, Rinder, Geflügel)



#### RAPID COMMUNICATIONS

#### Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

V M Corman<sup>1,2</sup>, I Eckerle<sup>1</sup>, T Bleicker<sup>1</sup>, A Zaki<sup>3</sup>, O Landt<sup>4</sup>, M Eschbach-Bludau<sup>1</sup>, S van Boheemen<sup>5</sup>, R Gopal<sup>6</sup>, M Ballhause<sup>4</sup>, T M Bestebroers, D Muth, M A Müller, J F Drexler, M Zambons, A D Osterhauss, R M Fouchiers, C Drosten (drosten@virology-bonn.de)1


- 1. Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
- 2. German Centre for Infection Research (DZIF), Germany
- 3. Virology Laboratory, Dr Soliman Fakeeh Hospital, Jeddah
- 4. TibMolbiol, Berlin, Germany
- 5. Department of Virology and Virosciences, Erasmus Medical Centre, Rotterdam, The Netherlands
- 6. Health Protection Agency (HPA), London, United Kingdom

#### RAPID COMMUNICATIONS


#### Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections

V M Corman¹-², M A Müller¹-², U Costabel³, J Timmª, T Binger¹, B Meyer¹, P Kreher⁵, E Lattwein˚, M Eschbach-Bludau¹, A Nitsche⁵, T Bleicker', O Landt', B Schweiger', J F Drexler', A D Osterhaus', B L Haagmans', U Dittmer', F Bonin', T Wolff', C Drosten (drosten@virology-bonn.de)1

- 1. Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
- 2. These authors contributed equally to this work
- 3. Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany
- Institute of Virology, University of Duisburg-Essen, Essen, Germany
   Robert Koch Institute, Berlin, Germany
- 6. Euroimmun AG, Lübeck, Germany 7. TibMolbiol, Berlin, Germany
- 8. Virosciences Laboratory, Erasmus MC, Rotterdam, the Netherlands



#### Bisherige Fälle von MERS-CoV Infektion



http://epidemic.bio.ed.ac.uk (A. Rambaut)

# Direkter Nutzen für das Öffentliche Gesundheitswesen: Beispiel Essener MERS-Patient mit Umgebungsuntersuchung, RKI kann auf Labormethodik zurückgreifen

# Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012

U Buchholz (buchholzu@rki.de)<sup>1,2</sup>, MA Müller<sup>3,2</sup>, A Nitsche<sup>1,2</sup>, A Sanewski<sup>4,2</sup>, N Wevering<sup>5</sup>, T Bauer-Balci<sup>6</sup>, F Bonin<sup>5</sup>, C Drosten (drosten@virology-bonn.de)<sup>3</sup>, B Schweiger<sup>1</sup>, T Wolff<sup>1</sup>, D Muth<sup>3</sup>, B Meyer<sup>3</sup>, S Buda<sup>1</sup>, G Krause<sup>1</sup>, L Schaade<sup>1</sup>, W Haas<sup>1</sup>

1. Robert Koch Institute, Berlin, Germany

2. These authors contributed equally to this work

- 3. University Bonn, Department of Virology, Bonn, Germany
- 4. County health department of Essen, Essen, Germany

5. Ruhrland hospital, Essen, Germany

6. County health department Oberbergischer Kreis, Gummersbach, Germany

Citation style for this article:

Buchholz Ú, Müller MA, Nitsche A, Sanewski A, Wevering N, Bauer-Baici T, Bonin F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G, Schaade L, Haas W. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill. 2013;18(8):pii-20406. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-20406

## Direkter klinischer Nutzen, z.B. Fallmanagement des Münchener MERS-Falls

A case of infection with Middle East Respiratory Syndrome coronavirus: a description of clinical features and virological analysis



Christian Drosten, Michael Seilmaier, Victor M Corman, Wulf Hartmann, Gregor Scheible, Stefan Sack, Wolfgang Guggemos, Rene Kallies, Doreen Muth, Sandra Junglen, Marcel A Müller, Walter Haas, Hana Guberina, Tim Röhnisch, Monika Schmid-Wendtner, Souhaib Aldabbagh, Ulf Dittmer, Hermann Gold, Petra Graf, Frank Bonin, Andrew Rambaut, Clemens-Martin Wendtner


#### Summary

Background The Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging virus involved in Published Online

### Fast alle frühen Fundamentaldaten zum neuen MERS-CoV stammen aus dem Verbund

OBSERVATION

Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines





The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies

Stefanie Gierer,<sup>a</sup> Stephanie Bertram,<sup>a</sup> Franziska Kaup,<sup>a</sup> Florian Wrensch,<sup>a</sup> Adeline Heurich,<sup>a</sup> Annika Krämer-Kühl,<sup>a</sup> Kathrin Welsch,<sup>a</sup> Michael Winkler,<sup>a</sup> Benjamin Meyer,<sup>b</sup> Christian Drosten,<sup>b</sup> Ulf Dittmer,<sup>c</sup> Thomas von Hahn,<sup>d,e</sup> Graham Simmons,<sup>f</sup> Heike Hofmann,<sup>a</sup> Stefan Pöhlmann<sup>a</sup>

**OBSERVATION** 



Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential

Eveline Kindler,\* Hulda R. Jónsdóttir,\* Doreen Muth,<sup>b</sup> Ole J. Hamming,<sup>c</sup> Rune Hartmann,<sup>c</sup> Regulo Rodriguez,<sup>d</sup> Robert Geffers,\* Ron A. M. Fouchier,<sup>f</sup> Christian Drosten,<sup>b</sup> Marcel A. Müller,<sup>b</sup> Ronald Dijkman,\* Volker Thiel<sup>a,g</sup>

Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus

Florian Zielecki, Michaela Weber, Markus Eickmann, Larissa Spiegelberg, Ali Moh Zaki, Mikhail Matrosovich, Stephan Becker, Friedemann Weber

Institute for Virology, Philipps University Marburg, Marburg, Germany<sup>a</sup>; Virology Laboratory, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia<sup>b</sup>


#### MERS-CoV ist deutlich empfindlicher gegen Interferon als SARS-CoV

Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus

Florian Zielecki, Michaela Weber, Markus Eickmann, Larissa Spiegelberg, Ali Moh Zaki, Mikhail Matrosovich, Stephan Becker,


Institute for Virology, Philipps University Marburg, Marburg, Germany<sup>a</sup>; Virology Laboratory, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia<sup>b</sup>

#### Replikation in Zellkultur unter Einfluß von Interferon



Trotz stärkerer Replikation und Zytopathogenität ist MERS-CoV nicht besser übertragbar als SARS-CoV

### Internationale Vernetzung



Z.B. Identifikation desMERS-CoV Rezeptors(2 Gruppen aus demVerbund beteiligt)

### Neues anti-CoV Wirkprinzip

OPEN & ACCESS Freely available online

PLOS PATHOGENS

### The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors

Susanne Pfefferle<sup>1,2,9</sup>, Julia Schöpf<sup>3,9</sup>, Manfred Kögl<sup>4,9</sup>, Caroline C. Friedel<sup>5,6</sup>, Marcel A. Müller<sup>2</sup>, Javier Carbajo-Lozoya<sup>3</sup>, Thorsten Stellberger<sup>3</sup>, Ekatarina von Dall'Armi<sup>3</sup>, Petra Herzog<sup>2</sup>, Stefan Kallies<sup>2</sup>, Daniela Niemeyer<sup>2</sup>, Vanessa Ditt<sup>2</sup>, Thomas Kuri<sup>7</sup>, Roland Züst<sup>8</sup>, Ksenia Pumpor<sup>9</sup>, Rolf Hilgenfeld<sup>9</sup>, Frank Schwarz<sup>4</sup>, Ralf Zimmer<sup>5</sup>, Imke Steffen<sup>10</sup>, Friedemann Weber<sup>7,11</sup>, Volker Thiel<sup>8</sup>, Georg Herrler<sup>12</sup>, Heinz-Jürgen Thiel<sup>13</sup>, Christel Schwegmann-Weßels<sup>12</sup>, Stefan Pöhlmann<sup>10</sup>, Jürgen Haas<sup>3,14\*</sup>, Christian Drosten<sup>2\*</sup>, Albrecht von Brunn<sup>3\*</sup>


Große vernetzte Studie, alle Mitgliedslabore beteiligt

# The Non-Immunosuppressive Cyclosporin DEBIO-025 Is a Potent Inhibitor of Hepatitis C Virus Replication In Vitro

Jan Paeshuyse,<sup>1</sup> Artur Kaul,<sup>2</sup> Erik De Clercq,<sup>1</sup> Brigitte Rosenwirth,<sup>4</sup> Jean-Maurice Dumont,<sup>3</sup> Pietro Scalfaro,<sup>3</sup> Ralf Bartenschlager,<sup>2</sup> and Johan Neyts<sup>1</sup>

Alisporivir (Novartis)

#### **Ebenso aktiv gegen MERS-CoV**





A. von Brunn, LMU München, unpublizierte Daten



## Feline infektiöse Peritonitis -Verfügbares und hochrelevantes Tiermodell-

Feline enteric coronavirus (FECV) | Feline infectious peritonitis virus (FIPV)















**Translation in die Tiermedizin?** 


#### **K22** treatment impairs DMV formation



#### MERS-CoV inhibition in primary human airway epithelial cells




## TMPRSS2 & Cathepsin L aktivieren Coronaviren: Neue Ansatzpunkte für die Therapieentwicklung



Glowacka et al, 2011; Simmons et al, 2011; Bertram et al, J.Virol., 2011; Bertram et al, 2012; Gierer et al, 2013, Bertram et al, 2013, Simmons et al, 2013

#### TMPRSS2 ist essentiell für H1N1 Influenzaviren: Neues therapeutisches Target



TMPRSS2 knock-out schützt vor Ausbreitung und Pathogenese von H1N1 Influenzaviren

Hatesuer et al, PLOS Pathogens, 2013


MOLECULAR AND CELLULAR BIOLOGY, Feb. 2006, p. 965–975 2070-7306/06/808.00+0 doi:10.1128/MCB\_26.3.965–975.2006 Copyright © 2006, American Society for Microbiology, All Rights Reserved. Vol. 26, No. 3

#### Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease

Tom S. Kim, Cynthia Heinlein, Robert C. Hackman, and Peter S. Nelson\*

Division of Human Biology<sup>1</sup> and Division of Clinical Research, Fred Hutchinson Cancer Research Center, Mailstop D4-100, 1100 Fairview Avenue North, Seattle, Washington 98109-1024

Received 12 September 2005/Returned for modification 21 October 2005/Accepted 4 November 2005




TMPRSS2 *knock-out* ohne Phänotyp in nicht-infizierten Tieren


# ADRP – Domäne als hocheffizienter Attenuierungsmarker, klarer Mechanismus über Interferon-Antagonismus, konserviert in allen CoV

The ADP-ribose-1"-monophosphatase domains of severe acute respiratory syndrome coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses


Thomas Kuri, <sup>1</sup>† Klara K. Eriksson, <sup>2</sup> Akos Putics, <sup>3</sup>‡ Roland Züst, <sup>2</sup> Eric J. Snijder, <sup>4</sup> Andrew D. Davidson, <sup>5</sup> Stuart G. Siddell, <sup>5</sup> Volker Thiel, <sup>2</sup> John Ziebuhr, <sup>6</sup> and Friedemann Weber, <sup>1,7</sup>

## ADRP Defektmutante ist apathogen in ACE2-transgenen Mäusen





SARS ADRP mutant




Mock


=> ADRP Defektmutanten als Lebendvakzinen



## Feline infektiöse Peritonitis -Verfügbares und hochrelevantes Tiermodell-

Feline enteric coronavirus (FECV) | Feline infectious peritonitis virus (FIPV)













**Translation in die Tiermedizin?** 

### Output

- >100 Publikationen
- Erklärung der Herkunft von MERS-CoV
- WHO-empfohlener MERS-CoV Diagnostiktest
- 2 antivirale Ziele für alle CoV, inkl. MERS
- Antivirale Ziele über CoV hinaus (Flu)
- Attenuierungsmarker für Lebendvakzinen
- DFG-Schwerpunktprogramm

